Articles Tagged With: Mifepristone
-
Supreme Court Signals Possible End to Abortion Rights Under Roe v. Wade
Access to safe and legal abortion likely will end for half of America by this summer when the U.S. Supreme Court is expected to decide on Mississippi’s 15-week abortion ban, according to reproductive healthcare providers, attorneys, and leaders. Both the Mississippi case and the Texas six-week abortion ban — which the court allowed to continue in December 2021 — will potentially lead to abortion bans in dozens of states. -
Mifepristone as an Adjunct to Misoprostol for Pregnancy Termination
In this prospective, double-blind, randomized, placebo-controlled trial, pretreatment with 200 mg of mifepristone 24 to 48 hours before labor induction using misoprostol significantly reduced time to delivery among demised fetuses between 14 and 28 weeks of gestation. Maternal complications were equivalent in both groups.
-
Changes to Medication Abortion Could Result in Pharmacy Dispensing of the Drug
The easing of the risk evaluation and mitigation strategy restriction on mifepristone will make it easier for women to obtain the drug and could allow for pharmacy dispensing of the drug. Pharmacists should have a seat at the table in the conversation on dispensing prescription medication. -
Researchers Say It Is Time to Drop REMS Restriction on Mifepristone
The risk evaluation and mitigation strategy (REMS) restriction on mifepristone has been burdensome for providers and patients, researchers noted. The REMS restriction exacerbates the stigma around abortion care, which already disproportionately affects communities of color and young people. -
Research Shows Low-Sensitivity Pregnancy Test Works Well After Medication Abortion
New research shows using a low-sensitivity pregnancy test after a medication abortion is both accurate and safe. The 1,000 mIU/mL low-sensitivity pregnancy test or the five-level multilevel pregnancy test can be used safely without a visit to a provider’s office or clinic. -
FDA Makes Medication Abortion Available Via Telehealth
The FDA enabled reproductive health providers to prescribe mifepristone, the abortion medication, via telemedicine — at least through the duration of the pandemic. The FDA approved lifting the requirement of in-person dispensing of mifepristone, since the COVID-19 pandemic presents additional COVID-related risks to patients and healthcare personnel when patients visit a clinic solely to receive a prescription.
-
FDA Lifts Restriction on Mifepristone Access
Federal rule had required women to pick up the drug in person only, even during the COVID-19 pandemic.
-
Supreme Court Decision Reinforces Barrier to Medication Abortion
A recent decision by the U.S. Supreme Court could make it more difficult for women to access medication abortions. In an unsigned brief order on Jan. 12, the Supreme Court said a district court should not have compelled the Food and Drug Administration to lift a requirement that mifepristone, the abortion pill, has to be picked up in person.
-
Report Details Effect of Mifepristone Labeling Change
New research indicates that for Texas providers and patients, the 2016 Food and Drug Administration’s (FDA) new labeling for the abortion drug mifepristone increased access options and brought the proportion of medication abortions in the state into alignment with national data.
-
A New Treatment for Early Pregnancy Loss
In a recent trial, researchers found that pretreatment with mifepristone followed by treatment with misoprostol resulted in a higher likelihood of successful management of first-trimester pregnancy loss than treatment with misoprostol alone. The rate of surgical evacuation also was reduced in the mifepristone pretreatment arm compared to the misoprostol-alone arm.